Anatara Lifesciences (ASX:ANR) — Material Events
ASX:ANR · 11 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Anatara Lifesciences Advances Anti-Obesity Trials, Secures $1.2M PlacementMedium
Anatara Lifesciences advances Anti-Obesity and GaRP projects, announces board change and $1.2m placement
23 Oct 2025
·Quarterly Activities Report and Appendix 4C
·70
Anatara’s AOC Compound Shows Promise in Pre-Clinical Weight Control StudyMedium
Anatara reports positive pre-clinical anti-obesity results; MOA study delayed to January 2026
17 Dec 2025
·Company Update
·70
Anatara Lifesciences Finalises 66 Million Share Placement, Issues Options to Lead ManagerMedium
Anatara Lifesciences completes Tranche 2 placement of 66.35 million shares and issues options to Lead Manager
26 Nov 2025
·Capital Raising
·70
Anatara Lifesciences Halves Loss, Advances Anti-Obesity Research Amid $1.2m Capital RaiseMedium
Anatara Lifesciences halves net loss, advances anti-obesity pre-clinical studies, completes $1.2m capital raise
25 Feb 2026
·Appendix 4D and Interim Financial Report
·70
Anatara Lifesciences’ GaRP Trial Misses Primary Target but Reveals Secondary GainsMedium
Anatara Lifesciences reports increased loss, Phase II GaRP trial misses primary efficacy endpoint but shows secondary benefits, initiates anti-obesity project
13 Aug 2025
·Appendix 4E and Annual Report
·70
Anatara Lifesciences Secures $1.2m to Advance Anti-Obesity ProgramMedium
Anatara Lifesciences raises $1.2m via discounted placement to fund Anti-Obesity project
1 Oct 2025
·Capital Raising
·70
Anatara Lifesciences Advances Patents Amid Mixed GaRP-IBS Trial ResultsMedium
Anatara Lifesciences reports mixed Phase II GaRP-IBS trial results, advances patents, and receives R&D tax refund
29 July 2025
·Quarterly Activities Report and Appendix 4C
·70
Anatara Lifesciences Navigates Mixed Anti-Obesity Data and Tight Cash PositionMedium
Anatara Lifesciences reports mixed Anti-Obesity preclinical results, plans Phase 1 study, cash at $0.7M
29 Apr 2026
·Quarterly Activities and Appendix 4C Cash Flow Report
·60
Anatara Lifesciences Issues 33.6 Million Shares in First Placement TrancheMedium
Anatara Lifesciences issues 33.6 million shares in first tranche placement
8 Oct 2025
·Capital Raising
·60
Anatara Lifesciences Secures $969K Boost for Anti-Obesity ResearchMedium
Anatara Lifesciences secures $969K R&D tax incentive to advance Anti-Obesity project
28 July 2025
·ASX Release
·50
No articles in this tier for the last 12 months.
Market Mentions
2
- appeared in market wrap coverage
These are market wrap articles where Anatara Lifesciences (ASX:ANR) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026
28 Feb 2026